Background {#Sec1}
==========

Chronic kidney disease (CKD) is highly prevalent among patients with congestive heart failure (CHF) and is associated with higher mortality rates \[[@CR1]\]. In the CHARM trials, for example, an estimated glomerular filtration rate (eGFR) \< 60 ml/min/1.73m^2^ was an independent predictor of cardiovascular death or admission for decompensated heart failure \[[@CR2]\].

Echocardiography can identify abnormalities in heart function or structure that are associated with kidney dysfunction \[[@CR3]\]. Abnormal left ventricular (LV) geometry, lower mid-wall fractional shortening, and higher LV mass index have been described among patients with CKD compared with patients with preserved renal function in a cohort of participants with heart failure with preserved ejection fraction \[[@CR3]\]. In other studies, echocardiographic parameters predicted cardiovascular events among CKD patients, although there was no net reclassification improvement when these parameters were added to a model including clinical and laboratory variables \[[@CR4]\].

Although these data are intriguing, the echocardiographic characteristics of patients across the spectrum of cardiac function -- with both preserved or reduced LV ejection fraction and with or without CHF -- have not been adequately described across different eGFR stages, especially in patients with mildly decreased eGFR. It is also uncertain whether echocardiographic parameters predict CKD progression. The objective of this study was to describe the echocardiographic characteristics of patients with preserved renal function and mild or moderate CKD referred for echocardiography, and to assess associations of echocardiographic parameters with changes in renal function.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

Patients were included if they had at least one trans-thoracic echocardiography with tissue Doppler imaging at a Partners affiliated healthcare facility between January 1st 2004 and January 6th 2014, were ≥ 18 years old at the time of echocardiography, and had at least one eGFR between 30 and 120 ml/min/1.73m^2^ during this time period. For patients who had more than one echocardiogram, the first one was used.

Patients on maintenance dialysis or a history of kidney or heart transplant were excluded, as were those without creatinine values from 365 days before to 90 days after echocardiography.

The study was designed to capture patients with preserved renal function and mild or moderate CKD (eGFR≥90, 60--89, 30--59 ml/min/1.73m^2^).

Data collection {#Sec4}
---------------

The Research Patient Data registry (RPDR), a registry of all patients followed at a Partners healthcare facility, was used to retrieve all encounters, medication prescriptions, laboratory tests, and echocardiography results conducted during this time period.

To avoid misdiagnosis of acute kidney injury at the time of baseline echocardiography as CKD, the average baseline creatinine was calculated using all the available creatinines for each patient from 365 days prior to 90 days after the index echocardiogram (16 values on average, median of 7). Baseline eGFR was calculated using the CKD-EPI equation.

Comorbidities and baseline data {#Sec5}
-------------------------------

Information on comorbidities was extracted using condition-specific diagnostic codes (International Classification of Diseases, 9th revision-Additional file [1](#MOESM1){ref-type="media"} Table S1). Comorbidities were diagnosed on the basis of relevant inpatient or outpatient diagnoses preceding the echocardiography date. As many echocardiograms are performed during a first admission for decompensated heart failure, any patient with a first CHF diagnostic code in the 30 days after the echocardiogram was considered to have baseline CHF.

The following baseline laboratory data were extracted (the values closest to the echocardiogram date, from 365 days before to 90 days after echocardiography): hemoglobin, albumin, calcium, phosphorus, urine albumin to creatinine ratios, and brain natriuretic peptide (BNP) levels.

We determined the use of angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), β-blockers, statins, aspirin, clopidogrel, and warfarin by matching the most recent outpatient medication lists with generic and brand name drugs.

Echocardiograms {#Sec6}
---------------

The following parameters were extracted from the echocardiography reports using automated text processing: LV ejection fraction, LV diastolic diameter, LV posterior wall thickness, interventricular septal thickness in diastole, LV mass (area-length method), LV mass index (corrected for body surface area), pulmonary artery pressure, right atrial pressure, left atrium diameter, aortic root diameter, concentric hypertrophy and regional wall motion abnormalities, right ventricular (RV) systolic function (preserved or reduced), and RV hypertrophy or dilatation (presence or absence). All echocardiogram reports were acquired and recorded using an American Society of Echocardiography-recommended scanning protocol with standard techniques. Although we initially planned to examine associations of diastolic dysfunction with CKD progression, tissue Doppler imaging results were image-embedded and not readily extractable.

We randomly reviewed 100 patient records to check the accuracy of automated extraction of diagnoses, medication, and echocardiographic parameters. Specificity was 100% and sensitivity was between 95 and 97% for the different echocardiographic parameters (most available information was captured using regular expression searches).

Outcomes {#Sec7}
--------

We retrospectively searched in the registry for available creatinine values or diagnostic codes post index echocardiography. The composite of doubling of serum creatinine, maintenance dialysis or kidney transplantation was the primary outcome because it is a standard, FDA-validated outcome. Mortality was the secondary outcome. We also analyzed associations between echocardiographic parameters and eGFR, using the latter as the exposure.

Clinical outcomes were identified from RPDR using diagnostic codes. The RPDR is continuously matched to the social security death index, a national database including all deaths in the United States. For the outcome of doubling of serum creatinine, creatinine values starting 30 days after the first doubling as well as the last available creatinine were screened for repeated/confirmed doubling to rule out potential AKI. Patients were censored at the last clinical visit or lab test.

Statistical analysis {#Sec8}
--------------------

Baseline characteristics across eGFR groups were compared using the χ^2^ test for categorical variables, and one-way analysis of variance or non-parametric trend tests for continuous variables.

In order to study the association between echocardiographic parameters and eGFR, we used linear regression for continuous echocardiographic variables or logistic regression for binary variables. Normality, linearity, and homoscedasticity assumptions were confirmed using graphical methods. The following covariates were included in multivariate models on the basis of known associations with the outcomes of interest, clinical intuition, and availability in the dataset: age, sex, race, history of hypertension, diabetes, coronary disease, CHF, and use of ACEI or ARB.

In order to assess event-free survival, the cohort was divided into quartiles for LV diastolic diameter, LV mass, LV mass index, left atrium diameter, and pulmonary artery pressure. Categorical variables or variables reported in intervals rather than as true continuous measurements were assessed in binary categories (RV systolic function, RV hypertrophy and dilation, and right atrial pressure) except for LV ejection fraction where the following cutoffs were used: \< 25%, 25--39%, 40--54%, ≥55%. The incidence of the composite renal outcome was calculated for each quartile. The χ^2^ test was used to compare the different groups. To assess associations of echocardiographic parameters with clinical outcomes, multivariable Cox proportional hazards regression was used. Proportional hazards assumptions were verified using graphical methods. Patients without available creatinine values or diagnostic codes for dialysis or transplantation were considered to have stable renal function. The following parameters were included in the baseline model: age, sex, race, baseline eGFR, history of hypertension, diabetes, coronary artery disease, CHF, and use of ACEI or ARB. The various echocardiographic parameters were then added to the model. Patients with missing echocardiographic parameters were excluded from the respective survival analysis.

We conducted three sensitivity analyses in the following subgroups: i) outpatients only---in order to exclude individuals with echocardiograms during an acute cardiac event; ii) individuals without CHF at baseline; iii) individuals with available follow-up creatinine values or diagnostic codes.

*P*-values \< 0.05 were considered statistically significant. SPSS software (version 20.0, SPSS Inc., Chicago, IL, USA) was used for all statistical analyses.

Results {#Sec9}
=======

Echocardiographic parameters in different eGFR groups {#Sec10}
-----------------------------------------------------

We identified 42,446 patients with at least one echocardiogram and one eGFR value between 30 and 120 ml/min/1.73m^2^. Of these, 31,173 had at least one creatinine value available from 365 days before to 90 days after the echocardiogram. 492 patients with a transplanted heart or kidney, 268 patients on dialysis at baseline, and 1194 patients who had a baseline eGFR \< 30 ml/min/1.73 m^2^ were excluded from the main analysis. The characteristics of the 29,219 patients with an eGFR ≥30 ml/min/1.73m^2^ at baseline are depicted in Table [1](#Tab1){ref-type="table"}. Mean time between echocardiography and serum creatinine was 2.3 ± 0.1 days. Patients with worse renal function were older, more commonly white, had a higher prevalence of hypertension, diabetes, coronary artery disease, or heart failure, higher urine albumin to creatinine ratios, and higher potassium and phosphorus levels. BNP levels were also higher with increasing creatinine.Table 1Baseline characteristics of the study patientsCharacteristiceGFR 90--120eGFR 60--89eGFR 30--59NResultNResultNResultPatients9864 (34%)12,731 (43%)6624 (23%)Outpatients4558 (46%)6124 (48%)2448 (37%)Age (years)986450 ± 1412,73164 ± 13662472 ± 12Male sex98644797 (49%)12,7316608 (52%)66243281 (50%)African American98641168 (12%)12,731949 (8%)6624523 (8%)Hypertension98643480 (35%)12,7316884 (54%)66244091 (62%)Diabetes mellitus98641308 (13%)12,7312307 (18%)66241902 (29%)CAD98643087 (31%)12,7315984 (47%)66243762 (57%)CHF98641733 (18%)12,7313369 (27%)66243081 (47%)COPD9864286 (3%)12,731454 (4%)6624319 (5%)PE9864520 (5%)12,731452 (4%)6624257 (4%)ACEI89531614 (18%)11,6423278 (28%)61752222 (36%)ARB8953330 (4%)11,642928 (8%)6175810 (13%)β-blocker89533618 (40%)11,6426190 (53%)61753902 (63%)Statin89532298 (26%)11,6425077 (44%)61753317 (54%)Aspirin89532993 (33%)11,6425287 (45%)61753373 (55%)Clopidogrel8953659 (7%)11,6421325 (11%)6175844 (14%)Warfarin8953940 (11%)11,6421852 (16%)61751168 (19%)Creatinine (μmol/l)986465 (57--74)12,73182 (73--94)6624115 (100--134)eGFR (ml/min/1.73m^2^)9864104 ± 1212,73176 ± 9662447 ± 8Albuminuria stage: - A1348213 (61%)544333 (61%)472188 (40%) - A2348100 (29%)544159 (29%)472191 (41%) - A334835 (10%)54452 (10%)47293 (20%)Hb (g/l)7115123 ± 238458127 ± 214301118 ± 21Albumin (g/l)733138 ± 7926139 ± 6518337 ± 6K^+^ (mmol/l)95224.0 ± 0.412,3124.0 ± 0.464484.1 ± 0.5Calcium (mmol/l)84912.20 ± 0.1810,9612.23 ± 0.1557962.23 ± 0.18Phos (mmol/l)39741.0 (0.8--1.2)41881.0 (0.9--1.2)29171.1 (0.9--1.2)BNP (ng/L)90690 (27--265)1610188 (62--480)1519349 (137--745)Results are presented as number (percentage), mean ± standard deviation, or median (interquartile range). eGFR, estimated glomerular filtration rate; N, number of patients with available data; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive lung disease; PE, pulmonary embolism (acute or chronic); ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; A1: albuminuria \< 30 mg/g of creatinine; A2: albuminuria 30--300 mg/g of creatinine; A3: albuminuria \> 300 mg/g of creatinine; Hb, hemoglobin; K^+^, potassium; Phos, phosphorus; BNP, brain natriuretic peptide. Percentages are within eGFR group and exclude missing values. The three eGFR groups were statistically different (P value for trend \< 0.001 for all parameters except sex)

Patients with worse renal function had lower LV ejection fraction, higher prevalence of RV systolic impairment, higher LV mass index, higher LV and left atrium diameter, more regional wall motion abnormalities, and higher prevalence of RV hypertrophy or dilated RV **(**Table [2](#Tab2){ref-type="table"}**)**. They also had higher pulmonary artery pressures, and higher prevalence of elevated right atrial pressure. eGFR was independently associated with all echocardiographic parameters analyzed in multi-variable models (Additional file [2](#MOESM2){ref-type="media"} Table S2**)**.Table 2Echocardiographic characteristics of the study patientseGFR 90--120eGFR 60--89eGFR 30--59CharacteristicNResultNResultNResultPreserved EF91617604 (83%)11,7308975 (77%)61924058 (66%)LVEF (%)916160 (55--60)11,73060 (55--60)619255 (45--60)LVd (cm)75764.66 ± 0.7295624.64 ± 0.8054114.70 ± 0.93LVPW (cm)52470.98 ± 0.2261411.04 ± 0.2334311.09 ± 0.25IVSd (cm)69181.02 ± 0.2487591.10 ± 0.2549751.15 ± 0.26LVM (g)3853161 (126--205)4229174 (135--223)2377186 (146--243)LVMi (g/m^2^)285785 (69--103)320492 (74--115)1705102 (81--128)LAd (cm)72993.66 ± 0.7292773.92 ± 0.7852454.14 ± 0.83PAP (mmHg)530922 (18--28)738525 (19--31)435928 (22--37)RAP \> 6 cm H~2~O3831283 (7%)4400449 (10%)2317372 (16%)Impaired RV systolic function7810430 (6%)9887789 (8%)5376717 (13%)Increased RV diameter7982728 (9%)10,1481114 (11%)5555907 (16%)RV hypertrophy4990117 (2%)5888171 (3%)2840172 (6%)ARd (cm)69463.09 ± 0.4789273.18 ± 0.4750523.18 ± 0.48RWMA6320348 (6%)7366718 (10%)3377540 (16%)Results are presented as number (percentage), mean ± standard deviation, or median (interquartile range). N, number of patients with available data; LVEF, left ventricular ejection fraction; EF, ejection fraction; LVd, left ventricular diastolic diameter; LVPW, left ventricular posterior wall thickness; IVSd, interventricular septal thickness in diastole; LVM, left ventricular mass (area-length method); LVMi, left ventricular mass index (corrected for body surface area); LAd, left atrium diameter; PAP, pulmonary artery pressure; RAP, right atrial pressure; RV, right ventricle; ARd, aortic root diameter; RWMA, regional wall motion abnormalities. Percentages exclude missing values. The three eGFR groups were statistically different (P value for trend \< 0.001 for all parameters except LVd; *p* = 0.01 for LVd)

Echocardiographic parameters in patients with and without history of CHF {#Sec11}
------------------------------------------------------------------------

A total of 8183 patients had history of CHF: 1733 (21%) with an eGFR ≥90, 3369 (41%) with an eGFR of 60--89, and 3081 (38%) with an eGFR \< 60 ml/min/1.73m^2^. The baseline and echocardiographic characteristics according to eGFR groups of patients with CHF are shown in Additional file [3](#MOESM3){ref-type="media"}: Table S3 and Additional file [4](#MOESM4){ref-type="media"}: Table S4.

In the subgroup of patients without CHF, prevalence of various comorbidities at baseline was lower compared with patients with CHF. In those without CHF, right atrial pressure levels were similar in all three eGFR groups. For all the other echocardiographic parameters, a significant linear trend was identified across the different eGFR groups but the prevalence of RV or LV systolic dysfunction was lower (Additional file [5](#MOESM5){ref-type="media"}: Table S5 and Additional file [6](#MOESM6){ref-type="media"}: Table S6).

Renal outcomes {#Sec12}
--------------

At least one follow-up creatinine (beyond day 90 from the index echocardiogram) or diagnostic code for dialysis/transplantation were available for 20,008 patients (68%). Median follow up was 48 months (interquartile range 20--87 months). A total of 1041 composite renal events were observed: 691 events with the creatinine doubling, 273 initiations of dialysis, and 77 kidney transplantations; 282 occurred in patients with an eGFR ≥90 (0.86 events per 100 patients-years), 348 in patients with eGFR between 60 and 89 (0.73 events per 100 patients-years), and 411 in patients with an eGFR \< 60 ml/min/1.73m^2^ (1.79 events per 100 patients-years).

The number of composite renal events that occurred in the 1st, 2nd, 3rd, and 4th quartile of each echocardiographic parameter is depicted in Fig. [1](#Fig1){ref-type="fig"}. An increase was observed in higher quartiles of LV and left atrial diameter, LV mass and pulmonary artery pressure but not of LV mass index. Lower LV ejection fraction groups also had higher renal event rates. However, in adjusted models, most LV parameters were not independently associated with the composite renal outcome, with the exception of the second quartile of LV diastolic diameter (Table [3](#Tab3){ref-type="table"}). In contrast, pulmonary artery pressure and RV systolic function and dilation were independent predictors of the composite renal outcome. The adjusted HR for impaired RV systolic function was 1.51 (95% CI 1.21--1.88, *p* \< 0.001), and for RV dilation 1.59 (95% CI 1.32--1.92, p \< 0.001).Fig. 1Percentage of patients with CKD progression by category of echocardiographic parameters. The incidence of the composite renal outcome (doubling of serum creatinine or initiation of maintenance dialysis or kidney transplantation) was calculated for each quartile of LVd, LVM, LVMi, LAd, and PAP. For LVEF, the following cutoffs were used: \< 25%, 25--39%, 40--54%, ≥55%. *P* values are for trend. LVEF, left ventricular ejection fraction; LVd, left ventricular diastolic diameter; RV, right ventricular; LVMi, left ventricular mass index (corrected for body surface area); LA d, left atrium diameter; PAP, pulmonary artery pressure. P for trend providedTable 3Adjusted associations of echocardiographic parameters with composite renal outcomes and mortalityParameterNumber of renal eventsAdjusted HR (95% CI) - Renal outcomes*p*Number of deathsAdjusted HR (95% CI) - Mortality*p*LVEFGroup 1 vs. 467 vs. 6491.18 (0.88--1.59)0.26423 vs. 56021.46 (1.31--1.63)\< 0.001Group 2 vs. 491 vs. 6491.06 (0.82--1.36)0.66803 vs. 56021.27 (1.17--1.38)\< 0.001Group 3 vs. 4160 vs. 6491.05 (0.87--1.26)0.641403 vs. 56021.09 (1.02--1.16)0.007LVdQuartile 2 vs. 1178 vs. 2080.77 (0.63--0.95)0.021805 vs. 22110.83 (0.78--0.89)\< 0.001Quartile 3 vs. 1211 vs. 2080.97 (0.79--1.19)0.781553 vs. 22110.80 (0.75--0.86)\< 0.001Quartile 4 vs. 1292 vs. 2081.02 (0.83--1.26)0.831872 vs. 22110.84 (0.78--0.90)\< 0.001LVMiQuartile 2 vs. 142 vs. 560.72 (0.47--1.08)0.11450 vs. 4580.93 (0.81--1.06)0.29Quartile 3 vs. 184 vs. 561.29 (0.90--1.84)0.17551 vs. 4580.97 (0.85--1.11)0.65Quartile 4 vs. 163 vs. 560.81 (0.54--1.22)0.31626 vs. 4580.95 (0.83--1.08)0.41PAPQuartile 2 vs. 1167 vs. 1151.31 (1.02--1.67)0.031452 vs. 10901.11 (1.02--1.20)0.02Quartile 3 vs. 1157 vs. 1151.67 (1.30--2.15)\< 0.0011374 vs. 10901.26 (1.16--1.37)\< 0.001Quartile 4 vs. 1223 vs. 1152.26 (1.77--2.88)\< 0.0012062 vs. 10901.73 (1.60--1.88)\< 0.001RV systolic functionReduced vs. preserved106 vs. 7431.51 (1.21--1.88)\< 0.001881 vs. 64941.61 (1.49--1.73)\< 0.001RV hypertrophyPresent vs. absent26 vs. 4171.33 (0.88--2.02)0.18204 vs. 39711.17 (1.01--1.35)0.04RV dilationPresent vs. absent149 vs. 7401.59 (1.32--1.92)\< 0.0011189 vs. 64141.45 (1.36--1.55)\< 0.001Adjusted Cox models. Hazard ratios are adjusted for age, sex, race, baseline eGFR, history of hypertension, diabetes, CAD, or CHF, and use of ACEI and/or ARB. Composite renal outcome includes doubling of serum creatinine or initiation of maintenance dialysis or kidney transplantation. For LVEF, the following cutoffs were used: \< 25%, 25--39%, 40--54%, ≥55%. HR, hazards ratio; CI, confidence interval; AA, African American race; eGFR, estimated glomerular filtration rate; HTN, hypertension; CAD, coronary artery disease; CHF, congestive heart failure; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; LVEF, left ventricular ejection fraction; LVd, left ventricular diastolic diameter; LVMi, left ventricular mass index (corrected for body surface area); PAP, pulmonary artery pressure; RV, right ventricle

Mortality {#Sec13}
---------

8780 patients died during the follow-up: 2118 (24% of deaths) among patients with an eGFR ≥90 (6.4 events per 100 patients-years), 3456 (39% of deaths) among patients with eGFR between 60 and 89 (7.2 events per 100 patients-years), and 3206 (37% of deaths) among patients with eGFR \< 60 ml/min/1.73 m^2^ (13.6 events per 100 patients-years).

In adjusted models, LV ejection fraction group, LV diameter quartile, pulmonary artery pressure quartile, and RV parameters were independently associated with mortality (Table [3](#Tab3){ref-type="table"}).

Sensitivity analyses {#Sec14}
--------------------

Adjusted results were qualitatively similar in analyses of the 13,130 outpatients (Additional file [7](#MOESM7){ref-type="media"}: Table S7). Results were also similar in those without baseline CHF (*n* = 21,036, Additional file [8](#MOESM8){ref-type="media"}: Table S8), except that RV hypertrophy was not significantly associated with mortality, and in patients with available follow-up renal tests or codes (*n* = 20,008, Additional file [9](#MOESM9){ref-type="media"}: Table S9).

Discussion {#Sec15}
==========

We assessed echocardiographic characteristics of patients with preserved renal function and mild or moderate CKD in a cohort of individuals referred for echocardiography. We found that patients with CKD have a higher prevalence of structural and functional LV and RV abnormalities, which are already apparent in early CKD (eGFR 60--89 ml/min/1.73m^2^). We also identified that RV systolic function or dilation and pulmonary artery pressure are independently associated with a composite renal outcome of serum creatinine doubling, dialysis, or transplantation. Both RV and LV echocardiographic features were associated with mortality.

Park et al. analyzed the CRIC population and found that decreasing renal function was associated with LV hypertrophy, abnormal LV geometry, diastolic dysfunction, but not with systolic dysfunction \[[@CR5]\]. Gori et al. described cardiac structure and function in 217 individuals with heart failure with preserved ejection fraction from the PARAMOUNT trial \[[@CR3]\]. They found that renal impairment was associated with abnormal LV geometry, higher LV mass or LV mass index, and lower mid-wall fractional shortening \[[@CR3]\]. Creatinine clearance was also identified as an independent predictor of heart failure with preserved ejection fraction in a retrospective study of patients with hypertension and preserved ejection fraction \[[@CR6]\]. In a cohort of post-myocardial infarction patients from the VALIANT trial, worse renal function was associated with smaller LV, larger left atrial volume, and higher LV mass index \[[@CR7]\]. In contrast, in hypertensive patients with asymptomatic diastolic dysfunction from the VALIDD and EXCEED trials, eGFR group was not associated with echocardiographic measures of LV structure and function \[[@CR8]\].

Our findings confirm most of these observations in a much larger population including patients with and without CHF. We also report a significant association of worse renal function with LV systolic impairment, and we expand the previous findings by looking at RV parameters and their association with CKD.

We found that only pulmonary artery pressure and parameters related to the RV are associated with CKD progression. The AASK study addressed this issue in African-American patients with pre-existing non-diabetic hypertensive CKD and showed that LV mass index was not associated with a combined outcome of doubling of creatinine or end-stage renal disease \[[@CR9]\]. On the contrary, a retrospective analysis of the Jackson Heart Study, also in an African-American population, showed a significant association of LV mass, but not LV ejection fraction or pulmonary artery pressure, with a composite outcome of eGFR decline \> 30% or progression to end-stage renal disease \[[@CR10]\]. A small cohort study in stage 3--5 CKD patients demonstrated that concentric LV hypertrophy was associated with progression to dialysis, whereas LV ejection fraction and increased left atrium diameter were associated with CKD progression, defined as eGFR decline \> 3 ml/min/1.73m^2^ annually \[[@CR11], [@CR12]\]. In addition, a study in 300 elderly patients showed that LV hypertrophy was independently associated with eGFR decline \> 5 ml/min/1.73m^2^ per year \[[@CR13]\]. In the ESCAPE trial, a significant correlation was identified between baseline creatinine levels and right atrial pressure levels in patients admitted with heart failure \[[@CR14]\]. Park et al., using magnetic resonance imaging, demonstrated that LV mass and concentricity, a measurement of abnormal cardiac size, were associated with eGFR decline and incident CKD \[[@CR15]\].

Discrepancies with our findings may reflect differences in baseline renal and heart function, demographic characteristics and the use of a clinical cohort in our study compared to highly selected prospective research or trial cohorts in the prior studies. Furthermore, renal outcomes were not defined in the same way. Lack of association between LV mass index and renal outcomes or mortality in our study may be due to values below hypertrophic levels for the majority of individuals. LV mass could be more reliably assessed with more advanced techniques, such as magnetic resonance imaging. Similarly, lack of association between pulmonary artery pressure and renal outcomes in the Jackson Heart Study may be due to relatively normal pulmonary artery pressure values among study participants.

Our findings extend these findings by demonstrating a significant, independent association between RV diameter or function and CKD progression in a population that primarily did not have CHF. Worsening RV function and elevated pulmonary artery pressures may be associated with higher renal vein pressures, a purported mechanism underlying the cardiorenal syndrome \[[@CR16], [@CR17]\]. Similarly, salt and water retention in the setting of decreasing eGFR may contribute to volume overload and increased renal vein pressures that may impair renal perfusion and cause ischemia-mediated sclerotic changes. On the contrary, LV dysfunction may not significantly impact renal function provided that renal perfusion pressure remains in an acceptable range. However, these findings are only hypothesis generating and need to be prospectively confirmed. Finally, we also report a significant association between mortality and abnormal RV structure or function. No prior data exist on the association between right heart parameters and mortality in patients with CKD, to our knowledge.

Our study has several limitations. It is a retrospective study of patients referred for echocardiography and may not reflect the complete spectrum of patients with preserved renal function or mild eGFR impairment since sicker patients are more likely to be referred for echocardiography and those with more advanced cardiopulmonary disease are more likely to have RV dysfunction. Furthermore, no information was available on the indication for the echocardiogram. Echocardiograms were ordered to answer specific clinical questions rather than to provide systemic assessment of cardiac structure and they were interpreted by multiple clinicians rather than by a core lab, raising the possibility of confounding introduced by wide inter-reader variability between sonographers. In particular, RV assessment is fraught with potential errors of judgment and high degree of inter-observer variability. Additionally, tissue Doppler imaging results, diastolic function, and valve structure and function were not extractable for most patients.

Index echocardiograms might have been conducted in the setting of decompensated CHF and may not reflect baseline cardiac status or could have been followed by acute changes in kidney function. However, our findings were qualitatively similar in a subgroup analysis including only outpatient echocardiograms in which these issues would be less likely. We similarly cannot rule out the possibility that addition of renin-angiotensin-system agents in individuals with more severe echocardiographic changes partly accounted for associations with CKD progression, although our results were adjusted for use of these agents at baseline. Furthermore, the clinical indication of the echocardiogram may have already caused changes in eGFR. Capture of medication changes during follow-up is not readily available to us at this time. Finally, there were no BP or proteinuria values available for most patients in this dataset, and no information was available on the cause of death. Nevertheless, a sample size several times larger than all prior cohorts, assessment of multiple echocardiographic parameters, and most importantly a sufficient number of outcomes to be powered to examine associations with CKD progression and mortality represent unique strengths of our analysis.

More studies are needed to prospectively confirm the identified associations and carefully evaluate the right heart with comprehensive assessment of the RV including lateral tricuspid annular systolic velocity and acceleration, fractional area and long-axis change, tricuspid annular systolic excursion, myocardial performance index, and lateral free wall peak systolic strain, as well as inferior vena cava diameter and distensibility \[[@CR18], [@CR19]\]. These results also merit analysis in the setting of advanced CKD (eGFR \< 30 ml/min/1.73m^2^).

Conclusions {#Sec16}
===========

In conclusion, structural and functional abnormalities of the right and left ventricle are more common in individuals with mild or moderate renal impairment and associated with mortality while RV function and structure are independently associated with CKD progression even in early stage CKD. Prospective studies with quantitative assessment of the RV are needed to validate our observations and better understand the underlying mechanisms.
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